Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Leflunomide versus Azathioprine for Maintenance Therapy of Lupus Nephritis

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Collaborators: AnHui ShengLi Hospital; Changhai Hospital; First Affiliated Hospital Bengbu Medical College; First Affiliated Hospital of Wenzhou Medical University; Qilu Hospital; Qilu Hospital of Shandong University; Second Affiliated Hospital, School of Medicine, Zhejiang University; Shanghai 10th People's Hospital; Shanghai Zhongshan Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Soochow University; The First Affiliated Hospital with Nanjing Medical University; Zhejiang University
• Treatments: Azathioprine; Leflunomide

Criteria

Inclusion Criteria:

• Aged 18 to 65 years

• Biopsy-proven proliferative lupus nephritis

• Disease activity, SLEDAI score ≥ 8 points

• Persistent proteinuria (≥ 1g/24h), with or without microscopic hematuria;

• Signed informed consent

Exclusion Criteria:

• Allergy to the LEF, CTX, AZA

• Recent treatment with high-dose glucocorticoids

• Weight <45kg

• Recent treatment with immunosuppressive drugs

• CNS( Central Nerve System) Lupus patients

• Hepatic failure patients

• Severely abnormal renal function or end-stage renal failure

• More exclusion criteria in the protocol